Tolvaptan phosphate is a drug used for the treatment of

cardiac edema Pulmonary edema, also known as pulmonary congestion, is excessive liquid accumulation in the tissue and air spaces (usually alveoli) of the lungs. It leads to impaired gas exchange and may cause hypoxemia and respiratory failure. It is due t ...

. It is a prodrug of

tolvaptan Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive hea ...

, formulated as the salt tolvaptan sodium phosphate, for

intravenous administration Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutrie ...

. Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration. It was developed by

Otsuka Pharmaceutical Co. (), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964. History OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through a ...

and was approved for use in Japan in 2022.

References

{{Cardiovascular-drug-stub Prodrugs Organophosphates Diuretics Chloroarenes Benzanilides Vasopressin receptor antagonists Benzazepanes